Join Programme Director Brian Wang and his team for a session, hosted by CELT, at the Leggate Lecture Theatre on September 26th, 1 PM - 2:30 PM, to hear about their newly launched programme thesis, Sustained Viral Resilience. This programme thesis describes an emerging ~£50 M funding programme from ARIA, a UK government R&D funding agency, and aims to create a new class of medicines: "innate vaccines." Innate vaccines prevent viral infection across a wide range of different viruses for months by durably strengthening the innate immune system. This event is open to all disciplines and career stages.
You might find the session especially valuable if:
· You conduct antiviral research and have ideas for a proposal
· You work in synthetic biology, materials chemistry, or systems biology and are interested in forming teams for the programme
· You work on platforms, models, or tools that could broadly accelerate innate vaccine development
· You help bring innovative medicines from bench-to-patient, whether that be through clinical trial design, patient engagement, or regulatory science innovation
· You're interested in joining the programme team for their open Technical Specialist role
· You've never heard of ARIA or the programme but you're interested in learning more
